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Abstract: Non-enzymatic modification of aminophospholipids by lipid  
peroxidation-derived aldehydes and reducing sugars through carbonyl-amine reactions are 
thought to contribute to the age-related deterioration of cellular membranes and to the 
pathogenesis of diabetic complications. Much evidence demonstrates the modification of 
aminophospholipids by glycation, glycoxidation and lipoxidation reactions. Therefore, a 
number of early and advanced Maillard reaction-lipid products have been detected and 
quantified in different biological membranes. These modifications may be accumulated 
during aging and diabetes, introducing changes in cell membrane physico-chemical and 
biological properties. 
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1. Introduction 
Life demands membranes. Biological membranes are dynamic structures that generally consist of 
amphipathic molecules bilayers held together by non-covalent bonds [1,2]. In eukaryotic cells, 
phospholipids are the predominant membrane lipids and are, from a topographic point of view, 
asymmetrically distributed across the bilayer [3–5]. Phospholipids consist of a hydrophilic head  
group with attached hydrophobic acyl chains. The variation in head groups and aliphatic chains  
allows the existence of more than 1000 different phospholipid species in any eukaryotic  
cell [6,7]. Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylinositol (PI) and cardiolipin (CL), as well as sphingomyelin (SM) and  
glycosphingolipids (GS) are the major phospholipid classes [1,2]. In most eukaryotic membranes,  
PC and PE represent together around 60%–85% of the phospholipid fraction, while the fraction of 
other phospholipids depends on the cell membrane and even on animal species [1,2,8,9]. Phospholipids 
play multiple roles. They constitute a permeability barrier, modulate the functional properties of 
membrane-associated activities, provide a matrix for the assembly and function of a wide variety of 
catalytic processes, and act as donors during the synthesis of macromolecules. The wide range of 
processes in which phospholipids are specifically involved explains the need for diversity in 
phospholipid structures and fatty acid composition [6,10]. This diversity requires complex metabolic 
and regulatory pathways [1,2]. Therefore, for example, eukaryotic cells invest around 5% of their 
genes to synthesize all of these lipids [9]. 
The various phospholipid classes that comprise cell membranes are distributed over both leaflets of 
the bilayer in a non-random fashion [3–5]. This is especially evident for the aminophospholipids, PS 
and PE, which preferentially reside in the plasma membranes’ inner leaflet [11,12]. Where does lipid 
asymmetry originate, and how is it maintained and regulated? What is the functional role of 
aminophospholipid asymmetry, and what are the consequences of the breakdown of regulatory 
processes that result in the exposure of aminophospholipids in the cells’ outer leaflet? Although these 
key questions mainly remain unanswered, recent studies have established that cells have developed a 
number of mechanisms to deal with this issue. Targeting phospholipids to specific membrane sites is 
essential for maintaining critical signal transduction cascades, cell shape, hemostasis, and  
homeostasis [12]. In particular, aminophospholipids have been implicated in a diverse array of 
processes ranging from cell proliferation to cell death, from catabolism to inflammation [12]. In this 
scenario, asymmetry is maintained by active ATP-dependent processes, suggesting that is critical to 
normal cell function. Specifically, aminophospholipid asymmetry is controlled by one or more specific 
mechanisms, which involve selective interactions between lipids and cytoskeletal proteins and an 
aminophospholipid-specific active transport system [11,12]. 
The acyl chains are composed of either saturated, monounsaturated or polyunsaturated hydrocarbon 
chains that normally vary from 14 to 22 carbons in length [13]. In eukaryotic cells from vertebrate 
species, the average chain length of a biological membrane is strictly maintained by around 18 carbon 
atoms, and the relative distribution between saturated and unsaturated fatty acids follows the ratio 
40:60 [14]. Polyunsaturated fatty acids (PUFAs) are essential components of cellular membranes in 
higher eukaryotes that strongly affect their fluidity, flexibility and selective permeability. Additionally, 
PUFAs affect many cellular and physiological processes in animals, including modulation of ion 
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channels and carriers, activities of membrane-associated enzymes, and regulation of gene expression, 
among others [13]. 
Thus, membrane composition (phospholipids classes’ distribution and fatty acid profile) is strictly 
and dynamically regulated. The mechanisms of the homeostatic regulation of the membrane 
composition, the mechanisms that create lipid asymmetry and their functional implications, and the full 
definition of the utility of the eukaryotic lipid repertoire are beginning to be understood, being an 
exciting and rapidly expanding field. 
2. Membrane Unsaturation and Lipid Peroxidation 
As a principle, chemical reactions in living cells are under strict enzyme control and are tightly 
regulated by the metabolic program. One of the attractors involved in biomolecular evolution is the 
minimizing of unnecessary side reactions. Nevertheless, uncontrolled and potentially deleterious 
reactions occur, even under physiological conditions. Oxidative damage is a broad term used to cover 
the attack upon biological molecules by free radicals—chemical species with one unpaired electron. 
Free radicals attack/damage all cellular constituents [14]. In this context, the susceptibility of 
membrane phospholipids to oxidative damage is related to two inherent traits, the physico-chemical 
properties of the membrane bilayer and the chemical reactivity of the fatty acids composing the 
membrane [15]. The first property is related to the fact that oxygen and free radicals are more soluble 
in the fluid lipid bilayer than in the aqueous solution. Thus, membranes contain an interior organic 
phase, in which oxygen may tend to concentrate. Therefore, these differences in solubility are 
important when considering the availability of oxygen/free radicals for chemical reactions inside living 
systems: Organic regions may contain more free radicals than aqueous regions [16,17] and, 
consequently, membrane lipids become primary targets of oxidative damage. The second property is 
related to the fact that PUFA residues of phospholipids are extremely sensitive to oxidation. Every 
membrane phospholipid contains an unsaturated fatty acid residue esterified to the 2-hydroxyl group of 
its glycerol moiety. Many of these are polyunsaturated and the presence of a methylene group between 
two double bonds renders the fatty acid sensitive to free radical-induced damage, their sensitivity to 
oxidation increasing exponentially as a function of the number of double bonds per fatty acid  
molecule [18,19]. Consequently, the high concentration of PUFAs in phospholipids not only makes 
them prime targets for reaction with oxidizing agents but also enables them to participate in long free 
radical chain reactions. 
Lipid peroxidation generates hydroperoxides as well as endoperoxides, which undergo 
fragmentation to produce a broad range of reactive intermediates called reactive carbonyl species 
(RCS) with three to nine carbons in length (see Figure 1), the most reactive being α,β-unsaturated 
aldehydes (4-hydroxy-trans-2-nonenal (HNE) and acrolein), di-aldehydes (malondialdehyde (MDA) 
and glyoxal), and keto-aldehydes (4-oxo-trans-2-nonenal (ONE) and isoketals) [20,21].  
2-Hydroxyheptanal (2-HH) is another major aldehydic product of lipid peroxidation of PUFAn-6, 
while 4-hydroxyhexenal (4-HHE) is generated in a lower yield. Additionally, a number of other short 
chain aldehydes are produced during lipid peroxidation through poorly understood mechanisms. These 
carbonyl compounds, ubiquitously generated in biological systems, have unique properties contrasted 
with free radicals [14]. For instance, compared with free radicals, reactive aldehydes have a much 
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longer half-life (i.e., minutes to hours instead of microseconds to nanoseconds for most free radicals). 
Further, the non-charged structure of aldehydes allows them to migrate with relative ease through 
hydrophobic membranes and hydrophilic cytosolic media, thereby extending the migration distance far 
from the production site. Based on these features alone, these carbonyl compounds can be more 
destructive than free radicals and may have far-reaching damaging effects on target sites within or 
outside membranes. 
Therefore, the highly unsaturated fatty acids present in cellular membranes are the most susceptible 
macromolecules to oxidative damage in cells, and this sensitivity increases as a function of their 
number of double bonds. In addition, the carbonyl compounds generated as lipid peroxidation-derived 
end products extend the membrane damage to other cellular constituents. 
Figure 1. General structures of principal reactive carbonyl species detected in biological systems. 
 
3. Non-Enzymatic Modification of Cellular Components: The Maillard Reaction-Derived 
Molecular Damage 
Carbonyl compounds react with nucleophilic groups in macromolecules like proteins and DNA, 
resulting in their chemical, non-enzymatic, and irreversible modification and finally in the formation of 
a variety of adducts and cross-links collectively named Advanced Lipoxidation Endproducts  
(ALEs) [22,23]. Thus, by reacting with nucleophilic sites in proteins (belonging basically to Cys, Lys, 
Arg, and His residues), carbonyl compounds generate ALE adducts such as MDA-Lys, HNE-Lys, 
FDP-Lys, and S-carboxymethyl-cysteine; and the cross-links glyoxal-lysine dimmer, and  
lysine-MDA-lysine, among several others. The accumulation of MDA adducts on proteins is also 
involved in the formation of lipofuscin. Thus, lipofuscin becomes a nondegradable intralysosomal 
fluorescent pigment formed through lipoxidative reactions [24]. In addition to proteins, lipid 
peroxidation-derived endproducts can also react with the exocyclic amino groups of deoxyguanosine, 
deoxyadenosine, and deoxycytosine to form various alkylated products [25]. Guanine is, however, the 
most commonly modified DNA base because of its high nucleophilicity. Some common enals that 
cause DNA damage, analogously to proteins, are MDA, HNE, and acrolein, among others. Thus, the 
most common adducts arising from enals are exocyclic adducts such as etheno adducts, and  
MDA-deoxyguanosine (M1dG). 
In addition to lipid peroxidation derived carbonyl compounds, reducing sugars and carbonyl 
compounds derived from carbohydrate oxidation can also react with the primary amino groups of 
macromolecules such as proteins and DNA, following the principles of the carbonyl-amine reaction 
(also named Maillard reaction) [22]. The early Schiff base and Amadori adducts (glycation reaction), 
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which form subsequently, slowly undergo a succession of intramolecular rearrangements, dehydration, 
and oxidation-reduction reactions to produce the terminal products termed advanced glycation end 
products (AGEs), which are often chemically irreversible, thus persisting throughout the life of the 
affected macromolecule [26,27]. More important, a major spin-off of studies on glycation during the 
1980s was the recognition that oxidative reactions, and by inference, oxidative stress, catalyzed the 
chemical modification of proteins and DNA by Maillard reactions in vivo [28]. 
In this scenario, it is likely that the amino group of aminophospholipids will also react with 
carbonyl compounds and initiates some of the reactions occurring in proteins and DNA, expanding the 
biological effects of the carbonyl-amine or Maillard reaction (see Figure 2). 
Figure 2. Protein, DNA and aminophospholipid damage resulting from carbonyl products 
of lipid peroxidation. Shown are examples of molecular adducts (Advanced Lipoxidation 
Endproducts, ALEs) generated by the reactive carbonyl compound glyoxal. 
 
Hence, Maillard reaction-derived molecular damage is a natural consequence of aerobic life. 
Maillard reaction products (MRPs, including AGEs and ALEs) induce the chemical, non-enzymatic 
and irreversible modification of cellular constituents, and they are part of the evidence for the 
existence of an “oxidative stress” in vivo. Little is known about molecular modification by MRPs, 
particularly regarding aminophospholipids. A current challenge is to establish the chemical structure of 
these modifications and the mechanisms for their formation, and to identify which factors control the 
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nature, selectivity, extent, irreversibility and biological-pathological consequences of the molecular 
modification occurring in vivo. 
4. Chemical Modification of Aminophospholipids by Carbonyl-Amine Reactions 
Recent reports indicate that, like proteins and DNA, aminophospholipids are also targets of 
Maillard-type reactions. In early studies, the formation of products resulting from the reaction between 
aminophospholipids and lipoperoxidation-derived aldehydes such as MDA and HNE were described, 
but the exact structure of the products was not established. In these works, it was established that the 
amount of free amino groups significantly decreased during oxidation of phospholipids, developing a 
brownish-yellow color attributed to a Maillard-type reaction [29]. It was also reported that free amino 
groups of PE disappeared during oxidation in proportion to the oxygen absorbed [30]. Probably, both 
findings can be attributed to the reaction of the PE amino group with carbonyls, mainly MDA 
produced by lipid oxidation, leading to Schiff base formation as assessed by fluorescence. So, during 
peroxidation, PE and PS formed fluorescent chromophores with maximum emission ranging from  
440 to 490 nm and maximum excitation between 360 and 400 nm [31,32]. Fluorescence development 
was related to (i) formation of thiobarbituric acid reactive substances (TBARS), especially MDA;  
(ii) reaction time; (iii) availability of reactive amino groups on the aminophospholipids, and  
(iv) antioxidant (alpha-tocopherol) content in an inverse fashion. These chromophores showed 
similarities to those formed in model membranes [33] or in rat liver mitochondrial and microsomal 
fractions peroxidized in vitro [31,32]. Furthermore, lipid extracts isolated from lipofuscin [34] and 
from tissues of lipid peroxidation-experimental models such as old, vitamin E deficient animals or 
animals stressed with highly unsaturated lipid diets, showed similar fluorescence properties [31,32]. 
Table 1 offers, chronologically, a summary of studies dedicated to the characterization of Maillard 
reaction-derived compounds on aminophospholipids. 
Using thin-layer chromatography (TLC), non-enzymatic modification of aminophospholipids by 
lipoperoxidation derived products were also detected in red blood cells (RBC) [35–42] and in eye lens 
membranes [43,44]. These modifications corresponded to a Schiff’s base adduct formed by  
cross-linking the PE and PS amino with MDA aldehyde groups, based on the following evidence:  
(i) A new lipid spot appeared between PS and PE; (ii) its intensity was proportional to MDA 
concentration both in vivo and in vitro; (iii) in selective staining procedures, it was phosphorus positive 
and ninhydrin negative; (iv) when this compound was exposed to acid vapors and then developed in a 
second direction, the “adduct” was resolved into two equimolar spots of PS and PE which were 
ninhydrin positive; (v) other non-amino phospholipids were ineffective in the formation of this 
compound; (vi) its fluorescence characteristics were compatible with a Schiff base conjugate formed 
between MDA and aminophospholipids; and finally, (vii) added antioxidants, blocking MDA 
formation, avoided its appearance. 
Lipid peroxidation leads to the formation of other aldehydes, such as HNE, able to react with 
aminophospholipids. Accordingly, the formation of fluorescent chromolipids was detected when HNE 
was incubated with aminophospholipids, microsomes and mitochondrial fractions [45,46]. Spectral 
characteristics of these chromolipids showed excitation maxima at 350–360 nm and emission at  
430 nm, with the fluorescence intensity being linearly related to the number of HNE molecules 
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reacting with aminophospholipids [45]. More recently, HNE potential capacity to react with 
aminophospholipids has been reported. Thus, by using TLC-high performance liquid chromatography 
(HPLC)-liquid chromatography (LC)-mass spectrometry (MS) techniques, it has been found that the 
main resulting compounds were a Michael adduct plus a minor Schiff base adduct, partly cyclized as a 
pyrrole derivative via a loss of water, with PE being more reactive than PS [46].  
Table 1. Summary of studies addressing the characterization of non-enzymatic 
aminophospholipid modification by carbonyl-amine reactions. 
Experimental model Analytical approach Structural characterization Ref. 
In vitro Studies 
Peroxidation of arachidonate and 
docosahexaenoate + synthetic dipalmitoyl 
phosphatidylethanolamine 
Fluorimeter 
Fluorescence chromophores  
(Ex 360 nm, Em 430 nm) 
[31] 
Rat liver mitochondrial and microsomal 
fractions peroxidized in vitro 
Fluorimeter 
Fluorescent chromophores  
(Ex 365–370 nm, Em 435–440 nm) 
[47] 
Methyl arachidonate/ methyl linolenate/ 
methyl linoleate/ Malondialdehyde + 
phosphatidylethanolamine/ 
phosphatidylserine (PE/ PS) 
Fluorimeter 
Fluorescent chromophores  
(Ex 365 nm, Em 435 nm) 
[32] 
Malondialdehyde + Red blood Cells (RBC) Fluorimeter 
Fluorescent chromophores  
(Ex 390–400 nm, Em 460 nm) 
[35] 
Lipid peroxidation of rat liver microsomes Fluorimeter 
Fluorescent chromophores  
(Ex 359 nm, Em 430 nm) 
[48] 
Lipid peroxidation-derived compounds Fluorimeter 
Fluorescent chromophores  
(Ex 360 nm, Em 435 nm) 
[33] 
Malondialdehyde + primary amines Fluorimeter 
Identification of 1-4-Dihydropyridine-
3,5-Dicarbaldehydes as model of 
fluorescent components in lipofuscin  
(Ex 375–405 nm, Em 435–465 nm) 
[49] 
4-Hydroxynonenal (4-HNE) + 
microsomes/mictochondria/phospholipids 
(PS and PE) 
Fluorimeter 
Fluorescent chromophores  
(Ex 360 nm, Em 430 nm) 
[45] 
Malondialdehyde (MDA) + serine 
Nuclear magnetic 
resonance (NMR) 
and (high 
performance liquid 
chromatography 
(HPLC) 
N-2-(Propenal)serine [50] 
MDA + ethanolamine NMR and HPLC N-(2-propenal)ethanolamine [51] 
Mixed liposomes of L-alpha-dilinoleoyl-
phosphatidylcholine (DiLinPC) and  
L-alpha-
Dilinoleoylphosphatidylethanolamine 
(DiLinPE) in oxidative conditions 
Fluorimeter and 
oxygen consumption 
monitored 
polarographically 
with a Clark-type 
oxygen probe 
Fluorescent chromophores  
(Exc 360 nm, Em 430 nm) 
[52] 
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Table 1. Cont. 
Experimental model Analytical approach Structural characterization Ref. 
In vitro Studies 
Glucose + PE and PS 
Liquid 
chromatography-
electrospray 
ionization-mass 
spectrometry (LC-
ESI-MS and TLC) 
Glycated aminoglycerophospholipids [53] 
Lens + oxidative conditions Fluorimeter and TLC 
MDA:aminophospholipid adducts  
(Ex 360 nm, Em 470 nm) 
[44] 
Glycoxidation and autoxidation of PE from 
RBCs 
Gas chromatography-
mass spectrometry 
(GC-MS) 
Carboxymethyl-ethanolamine  
(as marker of carboxymethyl-
phosphatidylethanolamine, CM-PE) 
[54] 
Glucose + phosphatidylethanolamine 
Gas-liquid 
chromatography-
mass spectrometry 
(GLC-MS) and 
HPLC with diode-
array detection 
(DAD) 
1-deoxy-1-(2-hydroxyethylamino)-D-
fructose derivatives 
[55] 
Glucose + PE/phosphatidylcholine (PC)-PE 
liposomes 
Thin layer 
chromatography 
(TLC), HPLC, NMR, 
fast atomic 
bombardment  
(FAB)-MS 
Deoxy-D-fructosyl PE [56] 
(2-aminoethyl)phenetydylphosphate and (2-
aminoethyl)ethylphosphate as model of 
aminophospholipids + carbohydrates 
HPLC, NMR Aminophospholipid glycation [57] 
PE and PS + glucose GC-MS 
N-(glucitol)ethanolamine and  
N-(carboxymethyl)serine 
[58] 
Human low density lipoprotein (hLDL) + p-
hydroxyphenylacetaldehyde  
(p-hydroxyphenylacetaldehyde (pHA), 
product of L-tyrosine oxidation by the 
myeloperoxidase system of macrophages) 
GC-MS pHA-ethanolamine [59] 
Glucose and 3-Deoxyglucosone + PE 
GLC-MS and  
HPLC-DAD 
Formation of a phospholipid-linked 
pyrrolecarbaldehyde 
[60] 
Carbohydrates + PE 
LC-ESI-MS,  
HPLC-DAD, and 
NMR 
PE-derived Amadori compounds [61] 
PE + 4,5(E)-epoxy-2(E)-heptenal 
(secondary product of lipid peroxidation) 
GC-MS, HPLC-MS, 
NMR 
Phosphatidylethanolpyrroles and 
phosphatidylethanol-2-(1-
hydroxypropyl)pyrroles 
[62] 
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Table 1. Cont. 
Experimental model Analytical approach Structural characterization Ref. 
In vitro Studies 
PE + 13-hydroperoxyoctadecadienoic acid 
and other oxidized poly unsaturated fatty 
acids (PUFAs) followed by phospholipase 
D-mediated hydrolysis 
LC-MS and NMR N-(hexanoyl)ethanolamine [63] 
Different species of PE + 4-hydroxy-trans-
2-nonenal (4-HNE)/  
4-hydroxydodecadienal (4-HDDE)/ 
4-hydroxyhexenal (4-HHE) 
GC-MS, TLC, 
HPLC, and NMR 
Aldehydes-PE.  
Different PE species are differently 
targeted by fatty aldehydes 
[64] 
PE + Isoketals (IsoK) LC-ESI-MS 
IsoK-PE pyrrole adducts and  
IsoK-PE Schiff base adducts 
[65] 
Fatty aldehydes released from plasmalogens 
after oxidation of cerebral cortex 
homogenates 
GC-MS N-heptadecyl-PE [66] 
PE + Glucose + Potential “antiglycative” 
compounds (protein glycation inhibitors, 
antioxidants, vitamins, etc.) 
LC-ELSD-MS 
Amadori-PE.  
Pyridoxal 5'-phosphate and 
pyridoxal/vitamin B6 derivatives) are 
the most effective antiglycative 
compounds 
[67,68] 
Acetoacetate + brain aminophospholipids 
TLC and 
spectrophotometry 
UV spectroscopy at 280 nm [69] 
Acetaldehyde-PE 
Density functional 
theory study 
Schiff base formation between PE and 
acetaldehyde 
[70] 
Liposomes and human high density 
lipoprotein (hHDL) particles in oxidative 
conditions 
LC-MS 
Isolevuglandins (IsoLGs)-, MDA-, 
4.HNE-, N-Acyl-, and  
N-carboxyacyl-PEs 
[71] 
In vivo Studies 
hLDL Fluorimeter 
Fluorescent chromophores AGEs-lipids 
(Ex 360 nm, Em 440 nm) 
[72] 
Rat liver aminophospholipids GC-MS 
Amadori aminophospholipids (as  
5-(hydroxymethyl)-2-furfuraldehyde; 
5-HMF) 
[73] 
Liver mitochondria from mammalian 
species 
GC-MS 
Carboxymethyl-ethanolamine  
(as marker of CM-PE) 
[74] 
hRBCs 
TLC, HPLC, NMR, 
FAB-MS 
Deoxy-D-fructosyl PE [56] 
RBC membranes GC-MS 
Glycation and carboxymethylation of 
aminophospholipids (PE and PS) 
[75] 
Glucose/lactose + PE; foods and biological 
samples  
Presence in foods (e.g., infant formula, 
chocolate) and in rat plasma 
HPLC-UV (labeling 
with 3-methyl-2-
benzothiazolinone 
hydrazone) 
Glycated-PE and lactose-PE [76] 
RBC and LDL LC-MS and NMR N-(hexanoyl)ethanolamine [63] 
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Much evidence demonstrates the in vitro and in vivo occurrence of the Schiff base, Amadori and 
AGEs-lipid products resulting from the Maillard reaction (see also Table 1 and Figure 3). The Schiff 
base formation between glucose and aminophospholipids was documented in experimental models and 
in human RBC membranes, plasma, and low-density lipoproteins (LDL) [53,77–79]. The existence of 
glycated aminophospholipids in its Schiff base form was confirmed by using HPLC LC-electrospray 
ionization (ESI)-MS. Reduction with NaBH3CN, shifting the retention time and increasing the detected 
mass of glycated lipids by two units, confirmed the identity of the major analyte as a Schiff base. 
Surprisingly, only the diacyl species became glycated and neither the alkylacyl nor the alkenylacyl 
were modified; furthermore, in contrast with in vitro experiments, PS glycation was not detected. 
Figure 3. Advanced glycation end products (AGEs)-lipid products resulting from the 
Maillard reaction. 
 
In vitro model reactions of D-glucose and PE demonstrated the formation of Amadori products, 
which were also detected in vivo [55–58,73]. Chromatographic and spectroscopic characterization 
unequivocally proved the existence of deoxy-D-fructosyl PE [55,56]. The formation of the  
Amadori product has also been demonstrated through the synthesis and characterization of  
N-(glucitol)ethanolamine (GE), a stable reduction product of glycated PE, detected in RBC  
membranes [58]; and by 5-(hydroxymethyl)-2-furfuraldehyde formation from the acid-treated 
phospholipid fraction as a stable derivative of an Amadori product, in this case being detected in rat 
liver lipid extracts [73]. 
Early immunological studies indicated the presence of MRPs covalently attached to 
aminophospholipids such as PE in LDL, although their structures remain unknown [72]. In addition, 
by using an ELISA assay, it was concluded that the majority of MRPs present in LDL were localized 
in the lipid phase. Nevertheless, subsequent analyses identified carboxymethyl-lysine (CML) as the 
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major AGE antigen in tissue proteins, and it was proposed that AGE-lipids could be actually 
immunologically cross-reactive carboxymethyl (CM) derivatives of PE and PS formed by 
phospholipid glyco- and lipoxidation, similarly to proteins [80]. So, by using a selected  
selective ion monitoring-gas chromatography-Mass spectrometry (SIM-GC-MS) assay for 
carboxymethylethanolamine (CME) [54,74,75,81] and carboxymethylserine (CMS) [58], the 
hydrolysis products of CM-PE and CM-PS, respectively, it was possible to demonstrate CME and 
CMS formation in vitro during the glycation of dioleoyl-PE under air and from linoleoylpalmitoyl-PE, 
but not from dioleoyl-PE, in absence of glucose. These data seem to indicate that carboxymethylation 
may proceed either from glucose or PUFA under oxidizing conditions. In experimental models, 
glucose, which is more resistant to autoxidation than PUFAs, was present at a 33-fold molar excess 
over free amino groups, whereas PUFA (linoleic acid) in PE was present in equimolar amounts with 
the amino group. So, it is difficult to anticipate which one of the routes, glycoxidation or lipoxidation, 
predominates in vivo, being CME and CMS, like CML [82], mixed AGEs and ALEs. The possible 
contribution of myeloperoxidase-catalyzed formation of CM groups from serine interaction with 
hypochlorite should not be dismissed [83]. In this line, it the possible contribution of PS moieties to 
glycoaldehyde generation, as precursor of CM groups, might be hypothesized. An alternative source of 
these compounds could be the oxidative cleavage of the Amadori compounds that would result from 
glycation of PE or PS. However, glycated PS has not been detected in vivo. CME and CMS were 
detected in RBC and liver mitochondria membranes, and also in urine [54,74,75,81]. 
The Maillard reaction can generate free radicals through autoxidative processes that, in turn, lead to 
protein damage [28]. Similarly, these processes, initially described for proteins, may be expanded to 
aminophospholipids, representing another mechanism for the initiation of lipid oxidation (see Table 2). 
Accordingly, much evidence indicates that the Maillard reaction on aminophospholipids enhances lipid 
peroxidation: (i) Autoxidation is usually accelerated by primary amines [52]; (ii) in liposomes, 
inclusion of PE was found to accelerate the Fe2+-dependent peroxidation [52]; (iii) in vitro, highest 
levels of fluorescence intensity were obtained by incubating dilinoleoyl-PE with glucose in oxidative 
conditions; dipalmitoyl-PE and dilinoleoyl- or dipalmitoyl-PC were ineffective in fluorescence 
generation independently of the presence/absence of glucose and oxidative conditions [84]; (iv) the 
presence of a carboxyl group on PS, or two in the case of carboxymethylated serine, may enhance its 
metal binding capacity, leading to increased metal-catalyzed lipid peroxidation [58]; (v) even in the 
absence of exogenously added transition metals or free radical generating systems, the formation of 
AGE-lipids is accompanied by oxidation of the unsaturated fatty acid side chains, suggesting that 
AGEs formation is a source of free radicals that leads to lipid oxidation [85]; and finally, (vi) the 
incorporation of glycated PE into LDL facilitates its peroxidation [79]. 
Despite the fact that non-enzymatic modification of aminophospholipids by glycation, 
carboxymethylation and lipid peroxidation has been described, they represent only a limited range of 
the possible products that can likely be formed by the Maillard reaction. 
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Table 2. Summary of studies on physico-chemical effects of non-enzymatic 
aminophospholipid modification by carbonyl-amine reactions. 
In vitro or in vivo 
experimental model 
Analytical 
approach 
Marker Finding Ref. 
Rat and human urine 
NMR and 
HPLC 
N-2-(Propenal)serine 
Direct evidence for oxidative 
decomposition of phospholipids 
by lipid peroxidation 
[50] 
Rat and human urine 
NMR and 
HPLC 
N-(2-propenal)ethanolamine 
Direct evidence for oxidative 
decomposition of phospholipids 
by lipid peroxidation 
[51] 
Glucose + PE/hLDL Fluorimeter 
Fluorescent lipid advanced 
glycosylation  
(Ex 360 nm, Em 440 nm) 
Increase of fluorescence 
associated with the progressive 
oxidative modification of 
unsaturated fatty acid residues 
[72] 
Lipids (PE and PS) and 
hLDL-advanced 
glycosylation 
GC-MS 
4-hydroxyhexenal and  
4-hydroxynonenal 
Lipids-AGE formation in close 
proximity to unsaturated fatty acyl 
groups leads to lipid peroxidation 
[85] 
Unilamellar vesicles 
with PE and PC + 
glyceraldehyde 
Time-
resolved 
fluorescence 
spectroscopy 
 
Aminophospholipid glycation 
increases the head-group hydration 
and lipid order in both regions of 
the membrane and lipid glycation 
is accompanied of lipid oxidation 
[86] 
Atherosclerotic plaques 
collected from both 
diabetic and  
non-diabetic subjects 
LC-ESI-MS Glycated PE 
Glycated aminophospholipids are 
the major LDL glycation products 
and increase LDL susceptibility to 
oxidation 
[87] 
Model systems and egg 
yolk products 
LC-ESI-MS 
Identification of  
PE-linked glucosylamines 
(Schiff-PE), Amadori 
products (Amadori-PE),  
5-hydroxymethylpyrrole-2-
carbaldehydes (Pyrrole-PE), 
and carboxymethyl- (CM-PE) 
as well as carboxyethyl- 
(CE-PE) derivatives 
Possible influence on emulsifying 
properties and oxidation resistance 
[88] 
Amadori-PE + linoleic 
acid 
LC-MS and 
colorimetry 
TBARs and lipid 
hydroperoxides 
Glycated-PE trigger lipid 
peroxidation via free radical 
reactions 
[89] 
RBCs from diabetic and 
healthy individuals 
LC-ESI-MS 
Schiff-PEs and  
Amadori-PEs, and detection 
of pyrrole-PE, CM-PE and 
CE-PE 
Increase in diabetes; glycated PE 
promotes lipid peroxidation of 
biomembranes 
[90] 
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Table 2. Cont. 
In vitro or in vivo 
experimental model 
Analytical 
approach 
Marker Finding Ref. 
Different species of  
PE + 4-HNE/4-HDDE/ 
4-HHE 
GC-MS, 
TLC, HPLC, 
and NMR 
Aldehydes-PE 
Different PE species are 
differently targeted by fatty 
aldehydes: the higher their 
hydrophobicity, the higher the 
amount of adducts made 
[64] 
PE/PC monolayers +  
4-HNE 
Alternating 
current (AC) 
polarography 
Physico-chemical state of a 
condensed PE-containing 
phospholipid monolayer and 
its interaction with apo A-I 
4.HNE-PE does not alter 
monolayer stability, but decreases 
apo A-I insertion into the 
monolayer 
[91] 
PC/PE mixture + 
Glucose + isolated 
membrane proteins 
Lipid-protein 
interactions 
Amadori-PE and  
Amadori-proteins, and  
lipid-protein interaction 
parameters 
Lipid glycation decreases the 
affinity of lipids for membrane 
proteins, induces structural 
rearrangements in the protein that 
makes it more sensitive to thermal 
unfolding and decreases the 
affinity between proteins and the 
surrounding phospholipids. 
[92] 
PE + Glucose + 
oxidative conditions 
LC-ESI-MS 
Glycated-PE + oxidation 
products 
Oxidation of glycated-PE occurred 
more quickly than the oxidation of 
non-glycated-PE probably because 
of the existence of more oxidation 
sites derived from glycation of 
polar head group. 
[93] 
PE + Glucose + 
oxidative conditions 
LC-MS-MS 
Identification of free 
radicals in oxidized and 
glycoxidized PE 
Presence of several sites 
susceptible to oxidation in 
glycated-PE which may be 
responsible for the increase in the 
oxidative reaction rate occurring 
in glycated compounds 
[94] 
5. Biological Significance of MRPs in Aminophospholipids 
The membrane lipid bilayer is not a simple permeability barrier and matrix for protein organization, 
but a dynamic component capable of initiating and maintaining essential metabolic processes. 
Considering the presence of free amino groups in aminophospholipids, and their ubiquity in all the 
biomembranes, a priori all of them may be modified by the Maillard reaction. In this way, biological 
processes involving aminophospholipids could be potentially affected by this non-enzymatic process. 
Among these, the following may be highlighted [1,3,4,12]: (i) Asymmetrical distribution of 
aminophospholipids in cellular and different subcellular membranes; (ii) translocation and lateral 
diffusion in the membrane; (iii) membrane physical properties; (iv) biosynthesis and turnover  
of membrane phospholipids; and (v) activity of membrane-bound proteins that require 
aminophospholipids for their function (see Figure 4 and Table 3). 
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Figure 4. Potential effects of aminophospholipid modification by carbonyl-amine reactions 
in biological membranes. 
 
Table 3. Summary of studies on biological effects of non-enzymatic aminophospholipid 
modification by carbonyl-amine reactions. 
Experimental model 
Analytical 
approach 
Marker Finding Reference 
MDA+RBCs and  
in vitro lipid 
peroxidation of RBC 
TLC 
MDA:phospholipid 
adducts 
Lipid peroxidation and MDA 
accumulation disturb organization of PS 
and PE in the human erythrocyte 
membrane bilayer 
[38] 
Erythrocytes of 
phenylhydrazine-treated 
rats 
TLC 
MDA:phospholipid 
adducts 
Externalization of PS and PE in the 
membrane bilayer and hypercoagulability 
[39] 
Glucose-treated RBC TLC 
MDA:phospholipid 
adducts 
Increase adduct formation and osmotic 
fragility in human RBCs 
[42] 
hRBCs from different 
age groups + MDA or 
H2O2 treatment 
 
Aminophospholipid 
translocase activity 
Decrease with age (defects in endogenous 
lipid asymmetry observed in aged human 
RBCs may be due to altered activity of the 
translocase) 
[95] 
Lipid extracts from 
platelet incubated PE + 
PS + 4-HNE 
LC-MS 
PE-4-HNE 
compounds 
Formation in cell membranes that could 
alter the phospholipase-dependent cell 
signalling 
[46] 
Glycated-PE LDL + 
THP1 cells 
(macrophages) 
Cell culture, 
LC-ESI-MS 
Glycated PE 
Glycated-PtdEtn promotes macrophage 
uptake of LDL and accumulation of 
cholesteryl esters and triacylglycerols 
[79] 
Oxidized-LDL + 
platelets 
TLC Aldehyde-PE 
Modified PE as the active component of 
oxidized LDL particles elicit a pronounced 
prothrombotic response by increasing the 
activity of the platelet prothrombinase 
complex 
[96] 
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Table 3. Cont. 
Experimental model 
Analytical 
approach 
Marker Finding Reference 
PE + 4-HNE and 4-
HDDE (4-hydroxy-
2E,6Z-dodecadienal) 
TLC and 
GLC 
4-HNE-PE and  
4-HDDE-PE 
Modified PE is poor substrate for secreted 
phospholipase A2 
[97] 
Human Plasma 
TLC and 
GLC 
4-HNE-PE and  
4-HDDE-PE 
Potential alteration of phospholipid-
dependent cell signaling 
[97] 
Amadori-PE + 
endothelial cells 
(HUVEC) 
Cell culture 
Cell proliferation, 
migration, and tube 
formation, and 
secretion of matrix 
metalloproteinase 2 
(MMP-2) 
Glycated-PE promotes vascular disease as 
a result of its angiogenic activity on 
endothelial cells 
[98,99] 
Human blood platelets GC-MS 
4-HHE-, 4-HNE-, 
and 4-HDDE-PE 
In vivo identification.  
Increase of platelet aggregation 
[100] 
A particularly interesting property of biomembranes is the asymmetric distribution of phospholipids 
across the bilayer. This is especially evident for the aminophospholipids, PS and PE, which are 
preferentially located in the membranes’ inner leaflet. Since choline phospholipids are generally more 
saturated than aminophospholipids, this asymmetry is accompanied by a non-random distribution of 
fatty acyl side-chains as well. Aminophospholipid asymmetry is controlled by specific mechanisms 
involving an ATP and Ca2+ dependent inward-directed pump known as aminophospholipid 
translocase, specific for the polar head group [12]. This suggests that the biogenesis and maintenance 
of the phospholipid asymmetry are important components of membrane homeostasis. So, defects in the 
normal asymmetric distribution of aminophospholipids may result in altered membrane surface 
properties that may have important physiological and pathophysiological consequences. As prominent 
examples of this, one could find the consequences in hemostasis and thrombosis due to exposed PS in 
activated platelets, and the apparent recognition and sequestration of PS-expressing cells by the 
reticuloendothelial system [11,39]. Abnormal distributions of aminophospholipids have been also 
reported for sickle [37] and iron deficient [36] cells, old RBC [35,40], RBC obtained from neonates, 
patients with chronic myeloid leukemia and diabetes mellitus [41,42], and also in tumorigenic and 
apoptotic cells [101]. The origin of perturbed aminophospholipid asymmetry in these pathologic cells 
is unclear, but it might be related to the aminophospholipid nonenzymatic modification described in 
some of these situations. 
PE constitutes a class of lipids, that when dispersed in pure form under physiological conditions, 
assemble into nonbilayer structures [102]. This contrast to lamellar phase-forming lipids, which readily 
form hydrated lamellar phases or bilayer structures when dispersed in aqueous media [102]. Lipids 
with a high propensity to form nonlamellar phases have been implicated in supporting transient local 
nonbilayer structures, which occur in some cellular processes such as transmembrane movement of 
ions and large molecules, membrane fusion, membrane enzymatic functions and cell division. 
However, at present no data are available on the effects of MRP-lipids in these properties. 
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Theoretically, aminophospholipid biosynthesis and degradation could also be affected by the 
Maillard reaction: PS is considered both an end product and a biosynthetic intermediate, since it serves 
as a precursor of PE, given that in eukaryotes, this phospholipid can be formed either by 
decarboxylation of PS—the major pathway for PE biosynthesis—or through incorporation of 
ethanolamine into PE via the CDP-ethanolamine pathway. PS synthase is located in the endoplasmic 
reticulum, whereas PS decarboxylase is strictly confined to the inner mitochondrial membrane, an 
important finding when accounting aminophospholipid modification in mitochondrial membranes. 
Finally, PE can be converted into PC by a PE N-methyltransferase, constituting a relevant pathway for 
PC biosynthesis. The consequences of the interference of biosynthetic pathways, if any, that result 
from the non-enzymatic modification of the polar head of aminophospholipids, remain unknown. How 
the Maillard reaction—on aminophospholipids—may affect the recognition and transport to other 
cellular or subcellular membranes by aminophospholipids-binding proteins is also unanswered. In 
contrast, some data are available from in vitro experiments, indicating alterations of the degradative 
pathway [56]. So, it was described that the hydrolysis of glycated PE by phospholipase A2 was not 
affected, but the hydrolysis by phospholipase C and D was reduced by 50%, in agreement with the fact 
that glycation affects the polar head but not the acylester bound. 
Although several membrane-bound proteins from different biomembranes possibly require 
aminophospholipids for their function, this fact could be particularly relevant for mitochondrion 
membranes because several electron transport chain complexes, such as Complex I, Complex III, 
Complex IV; and the adenine-nucleotide translocator, require binding or interaction with PE [103]. 
Thus, an increase in the levels of mitochondrial MRPs-lipids, e.g., CME, may lead to serious 
alterations in mitochondrial respiration and energy production. 
The potential effects of these modifications introducing changes in the structural organization of the 
lipid bilayer and/or changes in the physico-chemical and biological properties of the polar head of 
aminophospholipids remain to be extensively explored. Nevertheless, considering the serious 
alterations that can be derived from these non-enzymatic modifications, a priori, it can be  
expected that the levels of these modifications should be found in a low range, at least, in  
physiological conditions.  
6. Physiological Significance of MRPs in Lipids 
Studies reporting the levels of MRP-lipids in different biomembranes are limited, with RBC 
membranes being the more extensively studied model. For human RBC and plasma lipids, 1.2% and 
2.3%, respectively, of total PE in glycated form, were reported [77]. In another study, concentrations 
of glycated PE of 9% and 15% were described for RBC and plasma lipids [56]. However, this 
modification degree, considering that during the preparation and manipulation of lipids prior to 
analysis Schiff bases were not discharged, may be the result of an overestimation in the percentage of 
modified PE. Accordingly, the Amadori adducts measurement by GC-MS in aminophospholipids from 
human RBC revealed a concentration of 0.41 ± 0.11 mmol/mol ethanolamine, representing 0.03% in 
the glycated form of total PE [58]. With reference to AGE-lipids, only aminophospholipid 
carboxymethylation, namely CME and CMS formation, was quantified. So, the measurement of CME 
in human RBCs revealed a value of 0.14 mmol/mol ethanolalmine [54]. CMS was present at an about 
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three times higher concentration (0.44 mmol CMS/mol serine) [58]. So, CME was quantitatively a 
minor fraction of total ethanolamine, representing only about 0.01% of the modification of RBC 
membrane phospholipids, in agreement with data reported for phospholipid-MDA adducts representing 
0.06%–0.08% of total PE and PS (equivalent to 0.2% of total phospholipids) [40–42]. 
In urine, CME, CMS, MDA-ethanolamine (MDA-Etn), and MDA-ser were detected [50,51,54,58]; 
however, only the levels of CME [54] and MDA-Etn [51] were available. So, it was calculated that 
approximately 2.8 µmol of CME (300 µg) and 0.07 µmol MDA-Etn (5 µg) were excreted daily by a 
healthy human adult (considering a mean daily creatinine excretion of 1.4 g for a 70 kg subject). 
Based on the concentration of CME and MDA-Etn in RBC ghost membranes, ~0.14 and  
0.98 mmol/mol of PE, respectively, and the concentration of PE in RBC membranes, ~1 mg/mL of 
packed RBC (average molecular mass for PE, 800 Da), 0.18 nmol of CME/mL and 1.22 nmol of 
MDA-Etn/mL of packed erythrocytes can be estimated. Since the average 70 kg subject has about  
2 L of packed red cells and ~1% of red cell turnover/day (average red cell life span, 120 days), only 
about 4 nmol of the daily urinary excretion of CME, and 24 nmol of MDA-Etn, can be attributed to 
RBC membrane degradation. Anticipating that other modifications may be present in a similar extent, 
it may be estimated that RBC modifications only represent 1%–5% of the total recovered daily in 
urine. Consequently more than 95% may arise from the physiological turnover of membrane 
phospholipids in cells other than red cells, supposing the non-existence of dietary income. 
Accordingly, a concentration of 0.11 mmol of Amadori products/mol PE was found in the isolated 
lipid fractions from rat livers, representing a modification degree of about 0.008%–0.01% [73]. 
Furthermore, with the mitochondrion being the major site of reactive species production in the cell, it 
could be hypothesized that aminophospholipids from mitochondrial membranes could be damaged by 
carbonyl stress. Thus, CME from mitochondrial phospholipids was evidenced in ten mammalian 
species. The levels observed indicated that CME is quantitatively a minor fraction of total PE, 
representing only about 0.025%–0.035% modification of mitochondrial membrane phospholipids 
(considering that all animals are male young adults, and assuming that the mitochondrial 
phosphatidylethanolamine average is about 35%) [74]. 
The average inner-membrane surface area per mitochondrion (12.43 µm2), when multiplied by the 
average number of mitochondria per cell (n = 1312), shows that the average total inner-membrane 
surface area in the cell is nearly 11-fold greater than the cell surface area, despite the fact that the 
mitochondria occupy only 17% of the total cell volume [104]. In the adult rat, the total mitochondrial 
inner-membrane surface area in the major organs has been found to average 460 m2, contributed 
mainly by skeletal muscle (82% of the total), liver (8%), kidney (5%), heart (3%), brain (1%), and lung 
(1%) (59). On the other hand, recent studies in liver cell sindicate an average mitochondrial half-life of 
3.8 days, corresponding to the destruction of one mitochondrion per cell about every 11 min.  Similar 
conclusions apply in the case of kidney and heart muscle, both indicating that mitochondria are 
replaced many times during the lifetime of a given cell [104]. Hence, it can be inferred that cellular 
membranes, and particularly mitochondrial aminophospholipids, might be the major source of  
MRP-lipids in plasma and urine. In any case, and due to their low levels, it seems likely that  
MRP-lipids should be considered as biomarkers rather than important effectors of damage in tissues, at 
least in physiological conditions. 
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7. Significance of MRPs in Aminophospholipids in Aging and Pathological Conditions 
Similarly to proteins, MRP-lipids are of interest due to their potential contribution to the physiology 
of the aging process and age-associated diseases, such as diabetes and atherosclerosis (see Table 4). 
There is little evidence that demonstrates MRP-lipid accumulation in biological membranes during 
aging and lifespan. Examining the occurrence of phospholipid-MDA adducts in human RBCs and eye 
lenses of diverse ages, it was demonstrated that aged RBC showed significantly higher modifications 
than young erythrocytes (1.5% versus 0.2%) [35,40,96], similar to the results obtained for human 
cataractous lenses [43,44]. Furthermore, lipofuscin—a yellowish brown, lipid-rich, heterogeneous, 
cytoplasmic granule—shares characteristic autofluorescence with MDA-aminophospholipids, 
accumulating in a variety of animal tissues, particularly in metabolically active post-mitotic tissues, 
such as brain and heart, during their aging [34]. 
Table 4. Summary of studies on physiological and pathological effects of non-enzymatic 
aminophospholipid modification by carbonyl-amine reactions. 
Experimental model 
Analytical 
approach 
Marker Finding Reference 
Aged RBC Fluorimeter 
Fluorescent chromophores 
(Ex 390–400 nm,  
Em 460 nm) 
Increase with aging  
Altered physical and 
biochemical properties of 
aging cells (polymerization of 
plasma membrane proteins) 
[35] 
Lipids extracts from 
different tissues (heart, 
brain, liver, testis, kidney, 
adrenal cortex) 
Fluorimeter Fluorescent chromophores 
Increase with aging, and in 
pathological conditions  
(e.g., diabetes, hyperlipidemia) 
[15,34] 
RBC fromiron-deficient 
infants and animals 
Thin Layer 
Chromatography 
(TLC) 
Schiff’s base adduct due to 
reaction MDA + PS/PE 
Decrease RBC survival [36] 
RBC from the “sickle cell 
disease” 
Fluorimeter and 
TLC 
Fluoresecent chromophores 
& MDA:aminophospholipid 
adducts 
Increase adduct formation in 
sickle cell disease 
[37] 
Lipid extracts of the human 
cataractous and normal 
lenses 
Fluorimeter and 
TLC 
Fluoresecnt chromophores 
(Ex 365 nm, Em 460 nm) 
and MDA: 
aminophospholipid adducts 
Increase in human senile 
cataract 
[43] 
Aged human RBC 
membranes 
Fluorimeter and 
TLC 
Fluorescent chromophores & 
MDA: aminophospholipid 
adducts 
Increase with aging [40] 
RBC from diabetic patients TLC MDA:phospholipid adducts Increase adducts in diabetes [41] 
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Table 4. Cont. 
Experimental model 
Analytical 
approach 
Marker Finding Reference 
humanRBC (hRBC) from 
different age groups + 
MDA or H2O2 treatment 
 
Aminophospholipid 
translocase activity 
Decrease with age (defects in 
endogenous lipid asymmetry 
observed in aged human RBC 
may be due to altered activity 
of the translocase) 
[96] 
LDL from diabetic patients Fluorimeter  Increase in diabetes [72] 
Rat liver 
aminophospholipids in 
streptozotocin-induce 
diabetic rats 
GC-MS 
Amadori 
aminophospholipids  
(as 5-(hydroxymethyl)-2-
furfuraldehyde; 5-HMF) 
Increase in diabetes [73] 
RBC and plasma from 
diabetic and control 
subjects 
LC-ESI-MS 
Glycated 
aminophospholipids 
Increase in diabetes [77] 
Urine from diabetic and 
control subjects 
GC-MS 
Carboxymethyl-
ethanolamine  
(as marker of CM-PE) 
No increase in diabetes [54] 
Liver mitochondria from 
mammalian species 
GC-MS 
Carboxymethyl-
ethanolamine  
(as marker of CM-PE) 
CM-PE formation at 
mitochondrial level is 
associated with animal lifespan 
[74] 
hRBC from diabetic and 
control subjects 
GC-MS 
N-(glucitol)ethanolamine & 
N-(carboxymethyl)serine 
Adducts formed in vivo and 
increased in diabetes 
[58] 
hLDL from plasma and 
atherosclerotic aorta 
GC-MS pHA-ethanolamine 
Increase of pHA-PE in human 
atherosclerotic intima 
[59] 
RBC from diabetic and 
healthy individuals 
LC-ESI-MS 
Schiff-PEs, Amadori-PEs, 
pyrrole-PE, CM-PE and  
CE-PE 
Increase in diabetes; glycated 
PE promotes lipid peroxidation 
of biomembranes 
[90] 
Amadori-PE of a lipid 
extract from diabetic 
plasma 
QTRAP  
LC-MS-MS 
Amadori-PE Increase in diabetes [105] 
Plasma from: healthy 
volunteers, chronic 
hemodyalisis patients, 
Type II diabetic patients 
without chronic 
hemodialysis, and  
Type II diabetic patients 
with chronic hemodialysis 
HPLC-MS-MS Amadori-PE 
Increase of Amadori-PE in 
diabetes with or without 
chronic hemodialysis 
[106] 
Plasma from 
streptozotocin-diabetic 
rats 
LC-ELSD-MS Amadori-PE 
Increase in diabetes and 
decrease in streptozotocin-
induced diabetes and 
pyridoxal-treated rats 
[67,68] 
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Table 4. Cont. 
Experimental model 
Analytical 
approach 
Marker Finding Reference 
Retinas of streptozotocin-
induced diabetic rats 
GC-MS 
4-HHE-, 4-HNE-, and  
4-HDDE-PE 
Increase in diabetic animals [101] 
hRBC and blood plasma 
from healthy subjects and 
diabetic patients 
LC-MS-MS 
CM-PE and CE-PE as  
AGE-PE, and Amadori-PE 
No significant differences were 
observed in AGE-PE in RBC 
and plasma, whereas  
Amadori-PE concentrations 
were higher in diabetic patients 
[107] 
Blood plasma, kidney, 
RBCs, liver, pancreas, 
cerebrum, and cerebellum 
from streptozotocin-
induced diabetes rats 
LC-MS-MS Amadori-PE 
Increase in diabetes.  
Amadori-PE(18:0–20:4) is the 
PE species that acts as the 
most sensitive indicator 
[108] 
In another comparative-physiological approach, it was demonstrated that mitochondrial CME levels 
correlated with lifespan, i.e., levels of CME in short-lived are lower than those of long-lived  
mammals [74]. In this line, a previous study [109] which evaluated the effects of the aging rate of 
different mammalian species on the skin collagen concentration of pentosidine, a biomarker of 
glycoxidative protein damage, showed that although the highest pentosidine accumulation rates were 
observed in short-lived species, the absolute levels of pentosidine were smaller than those of long-lived 
species, similarly to the finding of low CME levels in short-lived species. All these data raise the 
question about the importance of absolute levels of protein and lipid oxidation markers before their 
accumulation rates. It is conceivable that short-lived species may exhibit higher rates of CME 
formation, but given the short half-life of aminophospholipids, rates of turnover will presumably be the 
dominant factor determining the levels of mitochondrial CME. Thus, the observed trends should be 
ascribed to interespecies differences in CME accumulation and/or phospholipid turnover rates. 
However, several aspects such as the urinary excretion as the expression of the turnover of damaged 
aminophospholipids, the implications of CME in mitochondrial and cellular metabolism, and the 
relationship of CME in mitochondria with the rate of aging remain to be explored.  
Diabetes induced a 2.5-fold increase of glycated aminophospholipids in the liver, and 0.025% vs. 
0.01%, in diabetes vs. control [73]. In a LC-MS-based study, it was reported that 1.2% and 2.3% of 
total PE were glycated in human RBC and in plasma lipids, respectively. Furthermore, these values 
were increased to 10% and 16% in diabetic patients, representing a 10-fold difference [77]. In these 
studies, special care was taken to not discharge Schiff bases during prechromatographic sample 
preparation. The Amadori products measurement by GC/MS showed about a three-fold increase in 
concentrations of GE in RBC lipids from diabetic patients relative to healthy controls [58]. In this line, 
it was reported that the concentration of phospholipid-MDA crosslink in RBC membranes was 
elevated approximately three-fold in diabetic subjects [41]. 
AGE-proteins play a key role as causative agents in the pathogenesis of diabetic  
complications [110]. In agreement with this concept, concentrations of CML and other AGEs are 
elevated in different tissues of diabetic patients, correlating with the severity of the chronic 
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complications. Since patients that participated in the referred study were free of complications [58,81], 
the lack of differences in CME levels, as well as CML, between control and patient populations was 
not an unexpected finding. Furthermore, and consistent with RBC data, neither urine CME nor CML 
concentrations were significantly increased by diabetes. So, further studies are needed to examine 
levels of carboxymethylated lipids in diabetic patients with more extensive vascular complications, 
predicting the existence of differences. In fact, it should be noted that a four-fold increase of  
MRP-lipids in LDL from diabetic patients vs. healthy subjects was reported by using enzyme-linked 
immunosorbent assay (ELISA), suggesting a greater increase in Maillard-type modification of 
aminophospholipids by diabetes [72], although responsible structure/s were not characterized. 
In this line, LDL glycation has been suggested to be responsible for the increased susceptibility to 
atherogenesis of diabetes subjects [111,112]. Thus, a recent report has indicated that PE glycation of 
LDL is accounted for completely by the known effect of LDL glycation on macrophage uptake, 
cholesteryl ester and triacylglycerol accumulation. Therefore, there is an increase in LDL atherogenic 
potential in the diabetic status [79]. Furthermore, and contributing to the pathogenesis of diabetic 
vascular complications, the interaction of RBC from diabetic rats with a receptor termed RAGE 
(receptor for AGEs) has been described [113]. A recent report indicates the recognition of 
“carboxymethyl” structures by RAGE [114]. This interaction could contribute to the shortened half-life 
of diabetic RBC when injected into normal animals, leading also to a localized increase in oxidative 
stress in the vascular wall.  The cause of this interaction could be explained by the exposition to the 
outer layer of the modified aminophospholipids, as previously described. However, the AGE structure(s) 
on the RBC surfaces mediating their interaction with the RAGE have not been characterized.  
8. Summary 
Membrane composition (phospholipids classes’ distribution and fatty acid profile) is strictly and 
dynamically regulated. The highly unsaturated fatty acids present in cellular membranes are the most 
susceptible macromolecules to oxidative damage in cells, and this sensitivity increases as a function of 
the number of their double bonds. Carbonyl-amine reaction-derived molecular damage is a natural 
consequence of aerobic life. Current data indicate the extension of carbonyl-amine reactions to 
aminophospholipids. Despite the fact that non-enzymatic modification of aminophospholipids by 
glycation, carboxymethylation and lipid peroxidation has been described, they represent only a limited 
range of the possible products that can likely be formed by the Maillard reaction. Due to their 
important role in cellular homeostasis, further studies are needed to elucidate the potential implications 
of these reactions on basic life processes. 
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